📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-10-15 17:28
0 analysed today
FollowTelegram
0
Today
151,853
All-time analysed
43,533
Positive
6,742
Negative
92,741
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
11 announcements match the current filters (relevance ≥ 5).
Wins ₹6.25 Cr Solar Module Purchase Order from Deon Energy
Gujarat Inject Kerala Ltd has secured a purchase order valued at approximately ₹6.25 crore from Deon Energy Limited. The contract entails the supply and arrangement of 8,065 solar modules of 620 Wp. The order represents roughly 13.6% of the company's TTM revenue of ₹46 crore and is slated for completion within October 2026. The contract does not involve related party transactions.
Confidence: HIGH
What changedGujarat Inject Kerala Ltd bagged a new ₹6.25 crore commercial contract to supply 8,065 solar modules to Deon Energy Limited.
Why it mattersProvides immediate revenue visibility equivalent to ~13.6% of TTM revenue and signals business diversification into the clean energy supply chain.
Total order value: ₹6.25 croreNumber of solar modules: 8,065Module capacity: 620 WpOrder vs TTM revenue: ~13.6%Completion date: October 2026
📅 Short termShort execution window requires prompt delivery by end of October 2026, which may reflect in the immediate quarter's revenue.
📈 Long termDemonstrates capability to win contracts outside traditional operations, though sustainable margin impact depends on repeat orders in the solar module segment.
⚠ Risk flags
- Tight execution timeline with target completion within October 2026
- Potential divergence from primary pharmaceutical business model
Key Highlights
Received purchase order valued at around ₹6.25 crore from Deon Energy Limited
Scope covers supply and arrangement of 8,065 solar modules of 620 Wp
Scheduled for completion by October 2026
Order value represents ~13.6% of TTM revenue (₹46 crore)
👀 What to Watch
Track execution completion within the stated October 2026 timeline and monitor upcoming Q2/Q3 FY27 quarterly results for revenue recognition and margin profile in the solar segment.
Wins ₹6.25 Cr Solar Panel Order from Deon Energy (~13.6% of TTM Revenue)
Gujarat Inject Kerala Ltd has secured a domestic purchase order valued at around ₹6.25 Crore (exclusive of GST) from Deon Energy Limited. The contract entails supplying 8,065 units of 620 Wp solar panels, to be executed within October 2026. This order represents approximately 13.6% of the company's TTM revenue of ₹46 Crore and roughly 20.8% of its current market cap of ₹30 Crore. The order does not involve any related-party transactions.
Confidence: HIGH
What changedThe company received a ₹6.25 Crore purchase order to deliver solar panels to Deon Energy Limited in October 2026.
Why it mattersThe ₹6.25 Crore contract provides revenue visibility, forming ~13.6% of TTM revenue, while reflecting business activity in the solar equipment supply segment despite the company's traditional pharma classification.
Order value: 6.25 CroresOrder volume: 8065 NOSPanel specification: 620 WpExecution timeline: October 2026Order vs TTM revenue: ~13.6%
📅 Short termPositive sentiment driver as the order accounts for over 20% of the firm's market cap and is slated for swift execution within the current month.
📈 Long termIndicates active trading or supply operations in the solar panel space; sustained growth will depend on recurring contracts and profitability metrics outside its legacy domain.
⚠ Risk flags
- Tight execution timeframe designated within October 2026
- Business line divergence: solar panel supply by an entity categorized under pharmaceuticals
Key Highlights
Purchase order value of around ₹6.25 Crores (exclusive of GST)
Contract scope covers 8,065 units of 620 Wp solar panels
Awarded by domestic entity Deon Energy Limited
Scheduled for execution within October 2026
Non-related party transaction with no promoter interest
👀 What to Watch
Monitor execution and revenue recognition in the upcoming Q3 FY27 financial results given the tight delivery schedule slated for October 2026.
Gujarat Inject Secures ₹4.86 Cr Solar Order and Capitalizes ₹20.76 Cr CWIP in Clean Energy Pivot
Gujarat Inject Kerala Ltd announced a major business pivot toward renewable energy, securing a ₹4.86 crore order from Zentaraa Infra Projects for 3,600 Solar PV modules to be executed in October 2026. The company capitalized ₹2,076.45 lacs (₹20.76 crore) as Capital Work in Progress (CWIP) toward a solar power project following an agreement with Soleos Energy. For FY26, total revenue reached ₹3,632.04 lacs (₹36.32 crore) and PAT rose to ₹181.41 lacs (₹1.81 crore), driven largely by its asset-light trading operations. No operational revenue was recorded from the solar generation project in FY26 as consideration discharge remains pending.
Confidence: HIGH
What changedGujarat Inject formally transitioned into renewable energy, amending its Object Clause and securing its first major solar supply order of ₹4.86 crore alongside ₹20.76 crore CWIP additions.
Why it mattersThe ₹4.86 crore order represents ~10.6% of TTM revenue (₹46 crore), and the ₹20.76 crore CWIP exceeds the company's entire net worth (₹12 crore), fundamentally shifting its profile from an asset-light trader to an infrastructure/clean-energy player.
Solar Order Value: ₹4.86 croreSolar PV Modules Count: 3,600Solar Project CWIP: ₹2,076.45 lacsOrder Value vs TTM Revenue: ~10.6%CWIP vs Net Worth: ~173%
📅 Short termThe announcement is likely to generate positive sentiment due to concrete commercial traction (₹4.86 crore order) slated for immediate execution in October 2026.
📈 Long termIf successfully executed, the pivot into solar power generation, BESS, and EV charging can transform the business from a low-margin trading firm into an asset-owning renewable energy company, though capital requirements will be high.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Project cash flows/revenue accrue only upon discharging consideration payable to the seller (Soleos Energy).
- Auditors flagged CWIP capitalization and its eventual transition to PPE as a Key Audit Matter (KAM).
- Sizeable capital commitments relative to a small net worth base (₹12 crore).
Key Highlights
Secured domestic purchase order worth ₹4.86 crore (exclusive of GST) for 3,600 Solar PV Modules from Zentaraa Infra Projects.
Recognized ₹2,076.45 lacs as Capital Work in Progress (CWIP) toward Solar Power Generation Project.
FY26 total revenue almost doubled to ₹3,632.04 lacs compared to ₹1,904.58 lacs in FY25.
FY26 PAT grew to ₹181.41 lacs from ₹101.72 lacs in the previous fiscal year.
Order execution scheduled for October 2026, while solar project capitalization was flagged as a Key Audit Matter by auditors.
👀 What to Watch
Monitor the timely execution of the ₹4.86 crore solar supply order in October 2026 and look for commercial commissioning and operational revenue commencement from the ₹20.76 crore CWIP solar assets in upcoming quarterly filings.
Wins ₹4.86 Cr Solar PV Module Order from Zentaraa Infra Projects
Gujarat Inject Kerala Ltd has secured a domestic purchase order valued at approximately ₹4.86 crore (exclusive of GST) from Zentaraa Infra Projects Private Limited. The order entails supplying 3,600 solar PV modules across required sites and is scheduled for execution within October 2026. The contract represents approximately 10.6% of the company's TTM revenue of ₹46 crore and around 16.2% of its ₹30 crore market cap. Notably, the company, traditionally classified under pharmaceuticals, continues to register revenue from solar supply contracts.
Confidence: HIGH
What changedSecured a new commercial purchase order for 3,600 solar PV modules worth ₹4.86 crore.
Why it mattersAdds revenue equivalent to ~10.6% of TTM revenue, scheduled for near-term delivery in October 2026.
Order value: around 4.86 CroresOrder volume: 3600 NOSOrder vs TTM revenue: ~10.6%Execution timeline: October 2026
📅 Short termExecution in October 2026 will likely reflect in the subsequent quarter's top line, supporting revenue stability.
📈 Long termDemonstrates ongoing diversification outside traditional pharma operations into solar trading/supply, though order predictability and operating margins remain key variables.
⚠ Risk flags
- Tight execution window (October 2026) carries potential logistics and delivery delay risks
- Business model shift away from core pharmaceutical identity
Key Highlights
Order value is approximately ₹4.86 crore (exclusive of GST)
Contract involves the supply of 3,600 units of Solar PV Modules
Scheduled for rapid execution within October 2026
Customer is domestic entity Zentaraa Infra Projects Private Limited, with no promoter or related-party interest
👀 What to Watch
Track Q3 FY27 revenue recognition to confirm successful dispatch within October 2026 and monitor margin profiles for these solar equipment supply orders.
Gujarat Inject Partners with UK-Based Storenergy to Explore Energy Storage in India
Gujarat Inject (Kerala) Limited has entered into a strategic business partnership with UK-based Storenergy Limited to explore Renewable Energy Storage Technology (REST) opportunities in India. The agreement establishes a framework to identify, evaluate, and develop potential storage projects. Commercial terms and financial arrangements for individual projects remain unfinalized and will be decided at a later stage. The company reported a net profit of Rs 1.25 cr on revenue of Rs 12.45 cr in the June 2026 quarter.
Confidence: MEDIUM
What changedSigned a strategic framework partnership with Storenergy Limited to evaluate Indian renewable energy storage opportunities.
Why it mattersSignals potential business diversification beyond core pharmaceuticals into green energy infrastructure, though financial impact remains unquantified.
Jun 2026 Quarterly Revenue: Rs 12.4545 crJun 2026 Quarterly PAT: Rs 1.2516 crCommercial Terms: not disclosedAnnouncement Date: August 24, 2026
📅 Short termMay drive speculative interest due to the renewable energy theme, but near-term financial impact is nil until binding project contracts emerge.
📈 Long termIf commercial projects materialize, it could establish a secondary growth driver, though execution feasibility outside core pharma remains untested.
⚠ Risk flags
- Exploratory agreement with no binding financial terms or confirmed project pipeline
- Diversification risk into unrelated renewable energy storage domain
- Funding and technology execution capabilities unproven
Key Highlights
Entered strategic partnership with UK-based Storenergy Limited for Renewable Energy Storage Technology (REST) in India.
Commercial terms for individual projects are not yet finalized and will be agreed upon at a later stage.
Transaction confirmed to be a non-related party transaction.
Company posted revenue of Rs 12.45 cr and PAT of Rs 1.25 cr in the Jun 2026 quarter.
👀 What to Watch
Track subsequent filings for definitive commercial contracts, capex commitments, and operational milestones in the energy storage business.
Gujarat Inject Kerala Signs Partnership with Storenergy Ltd (UK) for Thermal Energy Storage
Gujarat Inject Kerala Ltd has entered into a Strategic Business Partnership and Framework Agreement with UK-based Storenergy Limited to evaluate, develop, and pursue Thermal Energy Storage System (TESS) opportunities in India. Commercial terms and financial commitments have not yet been finalized and will be determined at a later stage. The deal represents an exploratory diversification into energy storage, distinct from its core operations which delivered Rs 12.45 cr revenue in the quarter ended June 2026.
Confidence: MEDIUM
What changedEntered a framework partnership with England-based Storenergy Limited to explore Thermal Energy Storage System opportunities in India.
Why it mattersSignals an exploratory foray into clean tech and energy storage, a major strategic diversification from its historical pharmaceutical business.
Jun 2026 Revenue: Rs 12.45 crJun 2026 Net Profit: Rs 1.25 crCommercial terms: not disclosed
📅 Short termInformational announcement that outlines intent without immediate cash flows or quantified revenue contribution.
📈 Long termLong-term value creation depends entirely on finalizing viable commercial terms, securing project pipeline, and operational execution in a new sector.
⚠ Risk flags
- Commercial terms and financial outlay are yet to be finalized
- Diversification into an unrelated industry (energy storage vs core pharma operations)
- Execution and funding risks in a nascent technology domain
Key Highlights
Entered into a strategic partnership agreement with Storenergy Limited, incorporated in England.
Purpose is to collaborate on evaluation, development, and pursuit of Thermal Energy Storage Systems (TESS) in India.
Commercial terms and financial consideration are not disclosed and will be decided at a later stage.
The transaction does not qualify as a related party transaction.
👀 What to Watch
Track subsequent disclosures for definitive agreements, firm capital expenditure plans, revenue-sharing models, and technological milestones.
Gujarat Inject Kerala Ltd to Pivot to Solar; Proposes Name Change to Regenova Renewtech Ltd
Gujarat Inject Kerala Ltd has scheduled an Extra Ordinary General Meeting (EGM) for August 12, 2026, to seek shareholder approval for a major strategic pivot. The company intends to change its name to 'REGENOVA RENEWTECH LIMITED' to reflect a new focus on solar-related activities, moving away from its pharmaceutical roots. This follows a previous name change proposal from April 2025 which the board now seeks to rescind as it did not adequately reflect the new business direction. The stock has seen a significant 461.9% price return over the last 12 months, likely anticipating this diversification.
Confidence: HIGH
What changedThe company is formally transitioning its business focus from pharmaceuticals to solar energy and seeking a corresponding name change.
Why it mattersA total industry pivot fundamentally changes the company's risk profile and valuation; success will depend on execution in a capital-intensive renewable energy sector versus its historical pharma operations.
EGM Date: August 12, 2026Cut-off Date: August 5, 202612-Month Price Return: 461.9%Previous Resolution Date: April 3, 2025
📅 Short termThe market may react to the formalization of the solar pivot, though the high 12-month return suggests significant speculative interest is already present.
📈 Long termThe long-term value depends on the company's ability to secure solar contracts and manage the transition from a pharma-based asset base to renewable energy infrastructure.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Industry pivot risk
- Execution risk in a new sector
- Lack of specific financial outlay for the solar venture
Key Highlights
EGM scheduled for August 12, 2026, to approve a pivot into solar-related activities
Proposed name change to 'REGENOVA RENEWTECH LIMITED' from 'Gujarat Inject Kerala Limited'
Rescinding a previous special resolution passed on April 3, 2025, for a different name change
Cut-off date for e-voting eligibility set for August 5, 2026
Remote e-voting period to run from August 8, 2026, to August 11, 2026
👀 What to Watch
Investors should look for detailed disclosures regarding the capital expenditure requirements, project timelines, and management's technical expertise in the solar sector to validate this business pivot.
414% Revenue Growth in Q1 FY27; Co. Rebranding to Regenova Renewtech for Solar Pivot
Gujarat Inject Kerala reported a massive 414.4% YoY revenue growth to 12.45 Cr in Q1 FY27, driven by its strategic pivot into the solar energy sector. Net profit surged to 1.25 Cr, which represents 69% of the total profit earned in the entire previous fiscal year (FY26). The company is formalizing this transition by proposing a name change to Regenova Renewtech Limited and has appointed Mr. Murli Shivshankaran Nair as Managing Director. While revenue declined sequentially from a peak Q4 FY26 of 30.70 Cr, the bottom-line remains significantly stronger than historical levels.
Confidence: HIGH
What changedThe company is officially transitioning from its legacy pharmaceutical identity to a renewable energy firm, backed by strong Q1 results and a new Managing Director.
Why it mattersThe pivot into solar PV distribution and power generation has fundamentally altered the company's growth profile and profitability, moving it away from the pharmaceutical industry where it was previously categorized.
Q1 FY27 Revenue: 12.45 CrYoY Revenue Growth: 414.4%Q1 FY27 PAT: 1.25 CrQ1 PAT as % of FY26 Full Year PAT: 69%Solar Project Capacity: 5MWQ4 FY26 Revenue (Sequential Peak): 30.70 Cr
📅 Short termThe market is likely to react positively to the massive YoY profit expansion and the clarity provided by the rebranding and leadership appointment.
📈 Long termThis represents a structural shift into the renewable energy sector; long-term success depends on scaling solar PV distribution and maintaining the improved margins seen in the recent quarters.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Significant sequential revenue decline (60% drop vs Q4 FY26)
- Industry pivot risk (transitioning from Pharma to Solar)
- Project-based revenue volatility
Key Highlights
Q1 FY27 Revenue grew 414.4% YoY to 12.45 Crore from 2.42 Crore.
Net Profit (PAT) reached 1.25 Crore, a massive jump from 0.07 Crore in Q1 FY26.
Q1 FY27 PAT accounts for 69% of the total FY26 full-year PAT of 1.81 Crore.
Company operates its own 5MW solar project in Jakasana, Mehsana (Gujarat).
Proposed name change to REGENOVA RENEWTECH LIMITED to reflect the shift from Pharma to Clean Tech.
👀 What to Watch
Monitor the consistency of quarterly revenues in the solar segment, as the 60% sequential drop from Q4 FY26 suggests potential project-based lumpiness. Watch for shareholder approval of the name change and the new MD's execution of the clean-tech roadmap.
Rs 1.24 EPS: Gujarat Inject Kerala Reports Q1 FY27 Results with Sequential Growth
Gujarat Inject Kerala Ltd has approved its unaudited financial results for the quarter ended June 30, 2026. The company reported a Basic EPS of Rs 1.24, representing a 44% increase from Rs 0.86 in the preceding quarter and a 10.7% increase from Rs 1.12 in the same quarter last year. Notably, the quarterly EPS of Rs 1.24 significantly exceeds the full-year FY26 EPS of Rs 0.05, suggesting a sharp recovery or high volatility in earnings. The statutory auditors, M/s. S Mandawat & Co., issued a limited review report with no material qualifications.
Confidence: HIGH
What changedThe company has transitioned into the new fiscal year (FY27) with a stronger quarterly earnings performance compared to both the previous quarter and the year-ago period.
Why it mattersFor a micro-cap pharmaceutical company with a 461.9% one-year price return, consistent earnings growth is critical to sustaining its current valuation and momentum.
EPS (Current Quarter): Rs 1.24EPS (Previous Quarter): Rs 0.86EPS (Year-ago Quarter): Rs 1.12EPS (Full Year FY26): Rs 0.05
📅 Short termThe stock may react positively to the sequential and year-on-year growth in EPS, especially given the low base of the previous full year's performance.
📈 Long termThe significant discrepancy between quarterly EPS (Rs 1.24) and full-year EPS (Rs 0.05) indicates high earnings volatility; long-term stability remains to be proven.
⚠ Risk flags
- High earnings volatility (FY26 full year EPS was only Rs 0.05 despite strong individual quarters)
- Limited financial transparency in the summary regarding revenue and margins
Key Highlights
Basic and Diluted EPS for Q1 FY27 stood at Rs 1.24.
EPS grew 44.18% sequentially from Rs 0.86 in the March 2026 quarter.
EPS grew 10.71% year-on-year from Rs 1.12 in the June 2025 quarter.
The reported quarterly EPS of Rs 1.24 is substantially higher than the full-year FY26 EPS of Rs 0.05.
Board meeting was efficient, concluding in 45 minutes (09:00 AM to 09:45 AM).
👀 What to Watch
Investors should examine the full financial statement to identify the drivers of the EPS growth, specifically checking if it stems from operational revenue or other income, given the high historical volatility in annual EPS.
Gujarat Inject Kerala Q1 FY27 Results: EPS Grows to 1.24 vs 1.12 YoY
Gujarat Inject Kerala Ltd reported its unaudited financial results for Q1 FY27 (ended June 30, 2026). The company posted a Basic EPS of 1.24, showing growth from 1.12 in the same quarter last year and 0.86 in the preceding quarter. This performance is a significant improvement over the full-year FY26 EPS of 0.05. Given the stock's 461.9% return over the past 12 months, these results provide critical fundamental data to assess the sustainability of the recent price rally.
Confidence: MEDIUM
What changedThe company has reported its first-quarter financial results for the fiscal year 2026-27, showing an upward trend in earnings per share.
Why it mattersThe results demonstrate operational profitability and EPS growth, which is essential for justifying the company's recent significant market outperformance.
Basic EPS (Q1 FY27): 1.24Basic EPS (Q4 FY26): 0.86Basic EPS (Q1 FY26): 1.12Basic EPS (Full Year FY26): 0.05
📅 Short termThe positive EPS growth trend (both YoY and QoQ) is likely to support current market sentiment in the short term.
📈 Long termLimited; this is a routine quarterly update, though sustained EPS growth will be necessary to maintain long-term valuation levels.
⚠ Risk flags
- Micro-cap volatility
- Garbled OCR in source document for historical figures
- High historical price appreciation risk
Key Highlights
Basic EPS for the quarter ended June 30, 2026, reported at 1.24
Quarter-on-Quarter EPS growth of approximately 44% from 0.86 in Q4 FY26
Year-on-Year EPS growth of 10.7% from 1.12 in Q1 FY26
Full-year EPS for the previous fiscal year was significantly lower at 0.05
Board meeting for result approval concluded in 45 minutes (09:00 to 09:45)
👀 What to Watch
Investors should monitor the full financial statement to determine if the EPS growth is driven by core pharmaceutical revenue or one-time gains, especially considering the high 12-month price return of 461.9%.
Gujarat Inject Kerala Ltd to Rename as Regenova Renewtech, Pivoting to Solar Sector
The Board of Gujarat Inject Kerala Ltd approved a name change to 'REGENOVA RENEWTECH LIMITED' on July 14, 2026, signaling a major strategic pivot. The company plans to shift its business focus from pharmaceuticals to solar-related activities. This proposal is subject to shareholder approval at the upcoming general meeting. While the stock has delivered a 461.9% return over the past 12 months, the financial details and execution plan for the solar venture remain undisclosed.
Confidence: HIGH
What changedThe company is rebranding and altering its Memorandum of Association to transition from a pharmaceutical focus to the renewable energy (solar) sector.
Why it mattersThis represents a fundamental shift in the company's business model and risk profile, moving from a legacy pharma business into a high-growth but capital-intensive renewable energy industry.
12-month Price Return: 461.9%6-month Price Return: 222.4%3-month Price Return: 39.6%Board Meeting Duration: 30 minutes
📅 Short termThe stock may experience volatility or thematic interest as the market reacts to the 'Renewable/Solar' pivot, which is currently a high-interest sector.
📈 Long termThe long-term success depends entirely on the company's ability to build expertise and scale in the solar industry, a complete departure from its existing pharmaceutical operations.
⚠ Risk flags
- Execution risk in a completely new industry
- Lack of disclosed financial targets for the new segment
- Potential for thematic speculation without underlying earnings support
Key Highlights
Board approved name change to REGENOVA RENEWTECH LIMITED on July 14, 2026
Company is pivoting from Pharmaceuticals to focus on solar-related activities
Stock has seen a significant 12-month price return of 461.9%
Board meeting concluded within 30 minutes (03:15 PM to 03:45 PM)
The 6-month price return stands at 222.4% as of the announcement date
👀 What to Watch
Monitor the upcoming General Meeting for shareholder approval and look for detailed disclosures regarding capital expenditure and the specific business model for the solar segment.
